Dr. Lal Pathlabs Limited

BSE: 539524 NSE: LALPATHLAB
Dr. Lal Pathlabs Limited - healthcare in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN L74899DL1995PLC065388 Incorporated 14 February 1995 ROC Delhi HQ New Delhi, Delhi, India
Active Listed - NSE: LALPATHLAB · BSE: 539524 Public Limited Company healthcare Nifty 500
Data last updated
Market Cap
₹32,323 Cr
LALPATHLAB · NSE
Share Price
₹1,932.70
+0.36% today
Revenue
₹2,763 Cr
FY 2025-26 · +12.3% YoY
EBITDA
₹752 Cr
Margin 27.2%
Net Profit
₹522 Cr
FY 2025-26 · +8.1% YoY
P/E (TTM)
56.9x
P/B 12.8x
ROE
21.8%
ROCE 27.4%
Debt / Equity
0.08
Interest cover 3.9x

About Dr. Lal Pathlabs Limited

Data last updated:

Dr. Lal Pathlabs Limited is a public limited company based in New Delhi, Delhi, India. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 14 February 1995 and has been in existence for over 31 years.

Dr. Lal Pathlabs is part of the Nifty 500 and BSE 500 indices. Its director Arvind Lal and family are #204 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L74899DL1995PLC065388. Its GSTIN is 07AAACD3377J1ZK (Delhi). The company holds 15 GST registrations, of which 10 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 539524 and NSE: LALPATHLAB.

The company has an authorised share capital of ₹200 Cr and a paid-up capital of ₹167.85 Cr. It was formerly known as Dr. Lal Pathlabs Private Limited. It is led by directors including Arvind Lal (Whole-Time Director) and Vandana Lal (Whole-Time Director).

Its last annual general meeting (AGM) was held on 25 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Block E Sector – 18 Rohini, New Delhi, Delhi, India – 110085.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,762.91 Cr, a growth of 12.2% compared to the previous year. For the same year it recorded a net profit of ₹522.06 Cr (net margin 18.9%) and EBITDA of ₹752.43 Cr (EBITDA margin 27.2%). The net worth stands at ₹2,508.14 Cr (up 15.4% YoY). Total assets are valued at ₹2,742.93 Cr (up 15.9% YoY).

The company has about 4,081 employees on its provident fund (EPFO) records. Its group structure includes 8 subsidiaries.

The company is associated with 1 brand: Dr Lal PathLabs. As per MCA filings, the company has open charges of ₹225.06 Cr and satisfied charges of ₹343.8 Cr on record. Court records list 64 cases involving the company, including 41 filed by the company and 23 filed against it; 20 cases are pending. The company has 43 deals on record (22 market trades, 17 secondary share transfers, 3 funding rounds), with disclosed funding of ₹45 Cr; the latest was in October 2025.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lalpathlabs.com.

Company details

CIN L74899DL1995PLC065388
Registration Number 065388
Incorporation Date 14 February 1995
ROC Delhi
Listing Status Listed - Listed on NSE (LALPATHLAB); Listed on BSE (539524)
Company Status Active
Date of Last AGM 25 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Dr. Lal Pathlabs has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74899DL1995PLC065388, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74899DL1995PLC065388Current
U74899DL1995PTC065388Previous
U74899DL1995PLC065388Previous
Key People
Arvind Lal Whole-Time Director Vandana Lal Whole-Time Director Archana Lal Erdmann Director

Recognitions & Rankings of Dr. Lal Pathlabs

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#228
Valuation
₹26,200 Cr
2023 #215 2022 #185 2021 #142
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 500 BSE 500

Contact details

Dr. Lal Pathlabs Limited's registered office is in New Delhi, Delhi. Its website is lalpathlabs.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    lalpathlabs.com
  • Social Media
  • Apps
  • Registered Address
    Block E Sector – 18 Rohini, New Delhi, Delhi, India – 110085
  • Industry
    Healthcare, Diagnostic Centers & Pathology Labs

To see the full contact details of Dr. Lal Pathlabs Limited, buy the company report.

Comprehensive company report
Dr. Lal Pathlabs Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Dr. Lal Pathlabs operates one associated brand: Dr Lal PathLabs. Each brand links to its own profile.

BrandDescriptionWebsite
Dr Lal PathLabs
Chain of pathology and radiology labslalpathlabs.com

Business activity

The main business activity of Dr. Lal Pathlabs is hospital and medical care. In detail, this covers medical and dental practice, nursing, pathology, blood bank services, etc..

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
QHospital and Medical CareQ2Medical and dental practice, Nursing, pathology, blood bank services, etc.

To see the full business activity and turnover split of Dr. Lal Pathlabs Limited, buy the company report.

Financials of Dr. Lal Pathlabs Limited

FY 2025-26 filings available

Dr. Lal Pathlabs Limited reported revenue of ₹2,762.91 Cr (up 12.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,763 Cr
+12.2% YoY
EBITDA
₹752 Cr
+8.2% YoY
Profit After Tax
₹522 Cr
+8.1% YoY
Net Worth
₹2,508 Cr
+15.4% YoY
Total Assets
₹2,743 Cr
+15.9% YoY
Total Debt
₹199 Cr
+26.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,7632,4612,2272,0172,0871,5811,330
Revenue growth+12.3%+10.5%+10.4%-3.4%+32.0%+18.9%-
EBITDA752696609490561436344
EBITDA margin+27.2%+28.3%+27.4%+24.3%+26.9%+27.6%+25.8%
Profit before tax669625505344475394311
Net profit522483358238345292226
Net profit margin+18.9%+19.6%+16.1%+11.8%+16.5%+18.5%+17.0%
EPS (₹)30.1358.2842.8528.6541.3734.9927.11
Balance sheet
Total assets2,7432,3662,1342,1192,0701,4261,147
Net worth2,5082,1731,8491,6661,5021,2451,033
Total debt1991572474205321500.00
Cash & bank910839830665618926569
Net working capital747689693560537852501
Cash flow
Cash from operations636569535456447398284
Cash from investing(422)(303)(24.27)(287)(449)(212)(26.11)
Cash from financing(264)(334)(414)(283)136(139)(190)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue798703660731670603597660
Revenue growth (YoY)+19.1%+16.6%+10.6%+10.7%+11.3%---
Other income31.9024.0024.4024.8028.1025.8025.1021.90
EBITDA248187149224192169154202
EBITDA margin+31.0%+26.6%+22.6%+30.7%+28.7%+28.0%+25.8%+30.7%
Depreciation44.4044.6042.1040.5034.6036.4035.5035.30
Interest6.306.107.204.804.705.005.306.00
Profit before tax229160124204181153138183
Tax58.2027.9032.9051.4047.10(2.10)40.2052.30
Net profit17013291.4015213415698.10131
EPS (₹)10.137.855.4118.0515.8518.5411.5815.48
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,6482,3522,1251,7691,8791,4911,274
Revenue growth+12.6%+10.7%+20.1%-5.8%+26.1%+17.0%-
EBITDA724665581461512407328
EBITDA margin+27.3%+28.3%+27.3%+26.0%+27.3%+27.3%+25.7%
Profit before tax660621483391461374303
Net profit527490347291345280223
Net profit margin+19.9%+20.8%+16.3%+16.5%+18.4%+18.8%+17.5%
EPS (₹)30.3359.4941.5435.0741.4233.6126.78
Balance sheet
Total assets2,6662,2852,0412,0851,9781,3211,107
Net worth2,4732,1341,8011,6901,4721,2171,016
Total debt1931511422813850.000.00
Cash & bank844768752534543889549
Net working capital712640628434466787492
Cash flow
Cash from operations606540478428426373272
Cash from investing(382)(293)31.91(288)(449)(195)(19.47)
Cash from financing(256)(325)(404)(270)141(136)(187)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue764675632700641577569631
Revenue growth (YoY)+19.3%+17.0%+11.1%+10.9%+11.5%---
Other income29.9037.0026.6022.8026.3025.2031.3024.20
Total expenses526494488484457418418437
EBITDA238182144215183159151194
EBITDA margin+31.2%+26.9%+22.7%+30.7%+28.6%+27.6%+26.5%+30.7%
Depreciation40.0042.7040.1038.5032.8034.6033.6033.40
Interest6.105.907.004.604.504.805.105.80
Profit before tax222170123195172145144179
Tax56.4028.8031.0049.1043.10(3.50)38.2050.20

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 04 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue798703660731670603597660
Revenue growth (YoY)+19.1%+16.6%+10.6%+10.7%+11.3%---
Other income31.9024.0024.4024.8028.1025.8025.1021.90
EBITDA248187149224192169154202
EBITDA margin+31.0%+26.6%+22.6%+30.7%+28.7%+28.0%+25.8%+30.7%
Depreciation44.4044.6042.1040.5034.6036.4035.5035.30
Interest6.306.107.204.804.705.005.306.00
Profit before tax229160124204181153138183
Tax58.2027.9032.9051.4047.10(2.10)40.2052.30
Net profit17013291.4015213415698.10131
EPS (₹)10.137.855.4118.0515.8518.5411.5815.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,7632,4612,2272,0172,0871,5811,330
Revenue growth+12.3%+10.5%+10.4%-3.4%+32.0%+18.9%-
Other income10193.4369.1741.7252.5551.3355.05
Total expenses2,0101,7661,6171,5271,5271,145987
Employee cost503456425377365274243
EBITDA752696609490561436344
EBITDA margin+27.2%+28.3%+27.4%+24.3%+26.9%+27.6%+25.8%
Depreciation16214214415010877.2072.81
Interest22.8022.3129.3637.5330.1816.0015.31
Profit before tax669625505344475394311
Tax15913314310312597.9382.91
Net profit522483358238345292226
Net profit margin+18.9%+19.6%+16.1%+11.8%+16.5%+18.5%+17.0%
EPS (₹)30.1358.2842.8528.6541.3734.9927.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16883.5983.4883.3783.4883.4683.35
Reserves & surplus2,3412,0891,7661,5831,4181,162974
Shareholders' funds (net worth)2,5082,1731,8491,6661,5021,2451,033
Minority interest33.1433.7636.0833.2535.4630.9621.22
Secured loans0.000.000.001532620.000.00
Unsecured loans1991572472662701500.00
Total debt1991572474205321500.00
Total liabilities2,7432,3662,1342,1192,0701,4261,147
Assets
Gross block2,1801,9381,8621,8071,726684574
Net block1,2561,1681,2281,3051,369447413
Capital work in progress6.543.485.654.9415.009.6111.38
Investments42332711415065.4659.30164
Inventories43.8636.1337.3133.8152.5442.5656.96
Sundry debtors11188.1277.4070.8285.4066.7051.39
Cash & bank balances910839830665618926569
Loans & advances79.8273.8967.9053.1054.1650.5850.91
Total current assets1,1441,0371,0138238101,086728
Total current liabilities397348320264273234227
Net working capital747689693560537852501
Total assets2,7432,3662,1342,1192,0701,4261,147
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash293361264378244197129
Net cash from operating activities636569535456447398284
Net cash from investing activities(422)(303)(24.27)(287)(449)(212)(26.11)
Net cash from financing activities(264)(334)(414)(283)136(139)(190)
Net change in cash(49.83)(68.31)97.20(114)13447.5867.33
Closing cash910839830665618926569
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.3%+10.5%+10.4%-3.4%+32.0%+18.9%-
EBITDA growth+8.2%+14.2%+24.4%-12.6%+28.5%+27.0%-
PBT growth+7.1%+23.6%+47.0%-27.6%+20.4%+27.0%+3.3%
Net income growth+8.1%+34.9%+50.2%-31.0%+18.3%+29.2%-
Revenue CAGR (3Y)+11.1%+5.7%+12.1%+14.9%+20.2%+14.4%+13.4%
EBITDA CAGR (3Y)+15.4%+7.5%+11.8%+12.6%+24.1%+18.2%+13.1%
Profitability & leverage
Net income margin+18.5%+20.0%+16.3%+12.0%+16.8%+18.8%+17.1%
Return on capital employed+27.5%+29.2%+25.6%+18.5%+29.5%+32.6%+31.4%
Return on net worth+21.8%+24.5%+20.6%+15.2%+25.5%+26.0%+23.0%
Debt / equity0.080.100.190.300.250.070.00
Long-term debt / equity0.050.050.090.160.150.050.00
Interest cover3.864.036.3111.056.674.465.65
Efficiency & per share
Fixed asset turnover1.341.301.211.141.732.513.04
Inventory turnover69.0867.0362.6246.7143.9031.7831.12
Debtors turnover27.7929.7430.0525.8227.4526.7825.43
EPS (₹)30.1358.2842.8528.6541.3734.9927.11
Dividend per share (₹)20.5024.0024.0012.0012.0020.0012.00
Book value per share (₹)149.69259.92221.53199.87180.17149.39126.81
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue764675632700641577569631
Revenue growth (YoY)+19.3%+17.0%+11.1%+10.9%+11.5%---
Other income29.9037.0026.6022.8026.3025.2031.3024.20
Total expenses526494488484457418418437
EBITDA238182144215183159151194
EBITDA margin+31.2%+26.9%+22.7%+30.7%+28.6%+27.6%+26.5%+30.7%
Depreciation40.0042.7040.1038.5032.8034.6033.6033.40
Interest6.105.907.004.604.504.805.105.80
Profit before tax222170123195172145144179
Tax56.4028.8031.0049.1043.10(3.50)38.2050.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,6482,3522,1251,7691,8791,4911,274
Revenue growth+12.6%+10.7%+20.1%-5.8%+26.1%+17.0%-
Other income11311266.3046.6053.1051.2757.61
Total expenses1,9241,6861,5441,3081,3661,083946
Employee cost475431403316321257232
EBITDA724665581461512407328
EBITDA margin+27.3%+28.3%+27.3%+26.0%+27.3%+27.3%+25.7%
Depreciation15413413682.0975.9469.7868.01
Interest22.0421.5028.6034.3828.6314.8314.66
Profit before tax660621483391461374303
Tax15212413698.4711693.9479.58
Net profit527490347291345280223
Net profit margin+19.9%+20.8%+16.3%+16.5%+18.4%+18.8%+17.5%
EPS (₹)30.3359.4941.5435.0741.4233.6126.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16883.5983.4883.3783.3583.3583.35
Reserves & surplus2,3052,0511,7171,6061,3891,154957
Shareholders' funds (net worth)2,4732,1341,8011,6901,4721,2171,016
Secured loans0.000.0083.332373450.000.00
Unsecured loans19315158.8843.9639.350.000.00
Total debt1931511422813850.000.00
Total liabilities2,6662,2852,0412,0851,9781,3211,107
Assets
Gross block2,0131,7741,701736667520449
Net block1,1431,0511,104361371300297
Capital work in progress6.543.485.654.9414.458.9911.29
Investments5134162131,2131,062171253
Inventories40.6032.2732.8523.3439.8438.9455.00
Sundry debtors13410587.4763.3267.0263.5450.25
Cash & bank balances844768752534543889549
Loans & advances76.6870.3864.1247.9149.5547.9849.08
Total current assets1,0959769366696991,039704
Total current liabilities383336308235233252211
Net working capital712640628434466787492
Total assets2,6662,2852,0412,0851,9781,3211,107
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash267344220351233189124
Net cash from operating activities606540478428426373272
Net cash from investing activities(382)(293)31.91(288)(449)(195)(19.47)
Net cash from financing activities(256)(325)(404)(270)141(136)(187)
Net change in cash(32.17)(77.75)106(131)11842.4265.30
Closing cash844768752534543889549
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.6%+10.7%+20.1%-5.8%+26.1%+17.0%-
EBITDA growth+8.8%+14.6%+26.0%-10.1%+25.8%+24.3%-
PBT growth+6.3%+28.8%+23.5%-15.2%+23.3%+23.6%+3.6%
Net income growth+7.5%+41.2%+19.1%-15.6%+23.1%+25.6%-
Revenue CAGR (3Y)+14.4%+7.8%+12.6%+11.6%+17.3%+13.3%+13.0%
EBITDA CAGR (3Y)+16.3%+9.1%+12.5%+12.0%+21.9%+16.7%+12.5%
Profitability & leverage
Net income margin+19.2%+21.2%+16.3%+16.5%+18.4%+18.8%+17.5%
Return on capital employed+27.6%+29.7%+24.8%+20.9%+29.7%+32.0%+31.1%
Return on net worth+22.1%+25.3%+19.9%+18.5%+25.7%+25.1%+22.9%
Debt / equity0.070.070.120.210.140.000.00
Long-term debt / equity0.050.020.020.080.060.000.00
Interest cover3.874.056.439.086.564.395.64
Efficiency & per share
Fixed asset turnover1.401.351.742.523.163.083.58
Inventory turnover72.6772.2275.6456.0047.7031.7330.76
Debtors turnover22.1024.3928.1927.1428.7826.2024.65
EPS (₹)30.3359.4941.5435.0741.4233.6126.78
Dividend per share (₹)20.5024.0018.0012.0012.0020.0012.00
Book value per share (₹)147.58255.32215.71202.70176.63148.43124.83

To see the full year-wise statements and ratios of Dr. Lal Pathlabs Limited, buy the company report.

Board of directors of Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs has 8 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Archana Lal Erdmann
Also directs: Genecode Health Private Limited
Director17 May 20197 Years 5 MonthsCurrent
Arvind Lal
Also directs: Archana Pharmaceuticals Private Limited, Kalmatia Sangam Travels Private Limited, Doon Mri Private Limited and 3 more
Whole-Time Director14 Feb 199531 Years 8 MonthsCurrent
Arun Duggal
Also directs: Davenport Management Consultants Services Private Limited
Director02 Feb 20233 Years 9 MonthsCurrent
Vandana Lal
Also directs: Archana Pharmaceuticals Private Limited, Kalmatia Sangam Travels Private Limited
Whole-Time Director14 Feb 199531 Years 8 MonthsCurrent
Rahul Sharma
Also directs: Porst Ware LLP, Chimes Aviation Private Limited
Director22 Jul 200521 Years 3 MonthsCurrent
Somya Satsangi
Also directs: TLGS Consulting Group Private Limited
Director08 Feb 20197 Years 8 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Auditor

Dr. Lal Pathlabs Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Deloitte Haskins & Sells LLPFY 2024117366W/W-100018

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 53.20%, foreign institutional investors hold 17.40%, domestic institutional investors hold 21.60% and retail and other public shareholders hold 7.80%.

Promoters: 53.20%DII (Domestic Institutional): 21.60%FII (Foreign Institutional): 17.40%Retail & Others: 7.80%
Sep 2026
QUARTER
53.20% Promoters
21.60% DII (Domestic Institutional)
17.40% FII (Foreign Institutional)
7.80% Retail & Others
Promoter holding - history
Now 53.20% · Sep 2026High 53.20% · Dec 2025Low 53.20% · Dec 2025
52%52.8%53.5%54.3%55%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 53.20%Mar 2026: 53.20%Jun 2026: 53.20%Sep 2026: 53.20%53.20%53.20%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters53.20%53.20%53.20%53.20%
Public46.80%46.80%46.80%46.80%

Charges & borrowings

Open charges
₹225.06 Cr
Satisfied charges
₹343.8 Cr
Breakdown by lending institutions
Axis Bank Limited₹185.00 Cr
Others₹40.00 Cr
State Bank of Baroda₹0.06 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
10 Nov 2021100507112Others₹40 CrOpen
09 Nov 2021100504850Axis Bank Limited₹185 CrOpen
19 Apr 198890239295State Bank of Baroda₹6.13 LakhOpen
24 Jun 2022100594143Hdfc Bank Limited₹250 CrSatisfied
07 Dec 2020100399810Others₹10 CrSatisfied

To see the full charge records of Dr. Lal Pathlabs Limited, buy the company report.

Total charge records: 17 View all charges

Deals & funding

Dr. Lal Pathlabs Limited has 43 deals on record (22 market trades, 17 secondary share transfers, 3 funding rounds), with disclosed funding of ₹45 Cr; the latest was in October 2025.

Total deals
43
Market trades
22
Secondary share transfers
17
Funding rounds
3
IPO
1
Disclosed funding
₹45 Cr

Deals on record (5 of 43)

WhenDealAmountParties
Oct 2025Market trade₹10.56 CrBuyer: Goldman Sachs Bank Europe Se - Odi
Seller: Goldman Sachs (Singapore) Pte - Odi
Jan 2025Market trade₹130.36 CrSeller: an individual
Oct 2022Market trade₹41.97 CrBuyer: Ishares Msci India Small-Cap Etf, an individual
Seller: Ishares Core Emerging Markets Mauritius Co, Ishares India Sc Mauritius Company
Dec 2015Market trade₹102.48 CrBuyer: GRD Securities Limited , N.K. Securities, Ashoka Pte Ltd
Seller: GRD Securities Limited , N.K. Securities
Mar 2014Secondary share transferUndisclosedBuyer: Garymuskan Estate Private Limited , an individual
Seller: Employees Welfare Trust Dr.Lal Pathlabs Private Limited

To see the full deal history of Dr. Lal Pathlabs Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Dr. Lal Pathlabs Limited was last rated by Crisil on 10 Aug 2020.

Rating agencyRated onRating
Crisil10 Aug 2020

To see the full credit ratings and regulatory alerts of Dr. Lal Pathlabs Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Dr. Lal Pathlabs Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Group structure & subsidiaries

Dr. Lal Pathlabs has 8 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

8
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Paliwal Diagnostics Private LimitedU26914UP1997PTC022257
Centrapath Labs Private LimitedU74220MP2019PTC049171
Dr. Lal Ventures Private LimitedU85100DL2018PTC342828
Suburban Diagnostics (India) Private LimitedU85110MH2002PTC136144
Paliwal Medicare Private LimitedU85110UP2006PTC031606
Aprl Pathlabs Private LimitedU85195GJ2019PTC110176

To see the full group structure of Dr. Lal Pathlabs Limited, buy the company report.

Employees & EPFO

Dr. Lal Pathlabs Limited has a workforce of 4,081 employees on its EPFO records as of Apr 01, 2024, across 3 active EPFO establishments.

Employee count
4,081
Active EPFO establishments
3
Employee growth
-0.1%

GST

Dr. Lal Pathlabs has 15 GST registrations: 10 active and 5 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
15
Active
10
Cancelled / inactive
5
GSTINStateStatusRegistered on
07AAACD3377J1ZKDelhiActive01 Jul 2017
29AAACD3377J2ZDKarnatakaActive08 Jun 2022
19AAACD3377J2ZEWest BengalActive15 Jun 2022
10AAACD3377J1ZXBiharActive21 Jun 2022

To see the full GST registrations and return filing status of Dr. Lal Pathlabs Limited, buy the company report.

Recent activity

Dr. Lal Pathlabs Limited has 32 board changes on record since 1995: 21 appointments and 11 cessations. The latest: Om Prakash Manchanda ceased to be Managing Director on 31 Mar 2025.

AGM
Dr. Lal Pathlabs Limited last Annual general meeting of members was held on 25 Jul 2026 as per latest MCA records.
Filing
Dr. Lal Pathlabs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi Ii.
Ceased
Om Prakash Manchanda ceased to be Managing Director.
Charges
A charge registered on 24 Jun 2022 via Charge ID 100594143 with Hdfc Bank Limited was fully satisfied on 10 Mar 2025.
Appointed
Ved Prakash Goel was appointed as CFO.
Appointed
Shankha Banerjee was appointed as CEO.
Ceased
Bharath Uppiliappan ceased to be CEO.
Ceased
Anoop Mahendra Singh ceased to be Director.
Ceased
Harneet Singh Chandhoke ceased to be Director.
Ceased
Saurabh Srivastava ceased to be Director.
Ceased
Sunil Varma ceased to be Director.
Appointed
Rajit Mehta was appointed as Director.

60 earlier events are in the company report.

News

Dr. Lal PathLabs: Subsidiary PUPL Completes Purchase Of Final 30% Stake In Centrapath Labs, Now Fully Owned.
13 Oct 2026 · Exchange Update
Dr. Lal Path Labs: Co. Completes Acquisition Of 80% Stake In Sunshine Healthcare Limited, Ghana; Shl Becomes A Step-down Subsidiary Of The Company.
26 Sep 2026 · Exchange Update

Frequently asked questions

Dr. Lal Pathlabs is an active public limited company based in New Delhi, Delhi, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 14 February 1995 (31+ years old) and is registered under CIN L74899DL1995PLC065388. Listed on BSE: 539524 and NSE: LALPATHLAB.

Dr. Lal Pathlabs reported revenue of ₹2,762.91 Cr for FY 2025-26 (up 12.2% YoY) based on consolidated financials.

Dr. Lal Pathlabs has 8 current directors:

The latest financial statements of Dr. Lal Pathlabs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 July 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Dr. Lal Pathlabs is 07AAACD3377J1ZK, registered in Delhi. The company has 15 GST registrations in all, of which 10 are active and 5 are cancelled or inactive. Other active GSTINs include 29AAACD3377J2ZD (Karnataka), 19AAACD3377J2ZE (West Bengal), 10AAACD3377J1ZX (Bihar).

The CIN (Corporate Identification Number) of Dr. Lal Pathlabs is L74899DL1995PLC065388. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Dr. Lal Pathlabs is a listed company as per MCA records. Its shares are listed on both BSE (code: 539524) and NSE (symbol: LALPATHLAB).

Dr. Lal Pathlabs has 64 court cases on record: 41 filed by the company and 23 filed against it. 20 are pending. Most are in the district courts.

Dr. Lal Pathlabs was incorporated on 14 February 1995, making it 31+ years old. It is registered with the Registrar of Companies, Delhi.

Dr. Lal Pathlabs has 43 deals on record (22 market trades, 17 secondary share transfers, 3 funding rounds), with disclosed funding of ₹45 Cr; the latest was in October 2025.